BRD2 and ovarian cancer: The gonadotropin hypothesis is supported by the decreased risk of ovarian cancer from a reduction of exposure to FSH and LH by the use of oral contraceptives, multiparity, and breast-feeding [7], and an increased risk of the disease with early menarche, late menopause, nulliparity, and the use of fertility drugs [6,9].